Craft

Genfit

Stock Price

€3.5

2024-05-10

Market Capitalization

€172.8 M

2024-05-10

Revenue

€20.2 M

FY, 2022

Genfit Summary

Company Summary

Overview
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases with a focus on the liver and gastroenterology worldwide. It offers diagnostic solutions in various therapeutic areas, such as metabolic diseases, liver diseases, non-alcoholic steato-hepatitis (NASH), cholestatic liver diseases, inflammation and autoimmune diseases, and inflammatory bowel diseases. The company’s lead pipeline product comprises GFT505, which is in Phase II clinical trials for the treatment of NASH. It is also developing TGFTX1 program that targets the RORgamma-t receptor, which directs IL-17 mediated immunity to treat inflammatory and auto-immune diseases; and TGFTX3 program for developing proprietary compounds, which activate the nuclear receptor Rev-Erba for metabolic and inflammatory diseases, including NASH and type 2 diabetes. The company also develops TGFTX4 program that inhibits the proliferation and the pro-fibrotic activation of primary human hepatic stellate cells; TGFTX5 program for chronic inflammatory bowel diseases; and SAN/GFT-2 program to develop molecules, which correct the mitochondrial dysfunction associated with certain pathologies comprising type 2 diabetes and kidney diseases. Genfit SA was founded in 1999 and is headquartered in Loos, France.
Type
Public
Status
Active
Founded
1999
HQ
Loos, FR | view all locations
Website
http://www.genfit.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Jean-Francois Mouney, Chairman of the Board of Directors and Chief Executive Officer of GENFIT, Co-Founder

    • Ph. D Dean Hum, Senior Executive VP and Chief Scientific Officer (CSO)

      • Nathalie Huitorel, Executive VP and Chief Financial and Administrative Officer (CFO)

        • Sophie Megnien, Chief Medical Officer (CMO)

          Operating MetricsView all

          Phase III Patients Enrolled

          1K

          Apr, 2018

          Patents (US)

          28

          FY, 2019

          Patents (Foreign)

          450

          FY, 2019

          LocationsView all

          2 locations detected

          • Loos, Nord-Pas-de-Calais Picardie HQ

            France

            885 Avenue Eugène Avinée

          • Cambridge, MA

            United States

            1 Alewife Center Suite 220

          Genfit Financials

          Summary Financials

          Revenue (H1, 2023)
          €11.5M
          Gross profit (H1, 2023)
          €14.8M
          Net income (H1, 2023)
          (€20.9M)
          Cash (H1, 2023)
          €111.8M
          EBIT (H1, 2023)
          (€19.3M)
          Enterprise value
          $136.4M

          Footer menu